The calcium/calmodulin-dependent protein kinases (CAMKKs) are upstream activators of CAMK1 and CAMK4 signalling and have important functions in neural development, maintenance and signalling, as well as in other aspects of biology such as Ca 2+ signalling in the cardiovascular system. To support the development of specific inhibitors of CAMKKs we have determined the crystal structure of CAMKK1 with two ATP-competitive inhibitors.
Introduction HIPK2) 12 . To aid the development of CAMKK1-or CAMKK2-specific inhibitors we have screened a library of kinase inhibitors against CAMKK1 and determined the X-ray crystal structure of CAMKK1 kinase domain in complex with two different inhibitors. Despite the high sequence similarity between CAMKK1 and CAMKK2 (70% over the kinase domain), comparison of the inhibitor-bound CAMKK1 structures with the existing structures of CAMKK2 reveal small but exploitable differences between the ATP-binding sites that might be used for the future design of specific inhibitors. 
Results

Identification of kinase inhibitors that are potent inhibitors of CAMKK1
Highly pure CAMKK1 kinase domain protein (residues Gln124-Lys411, hereafter called CAMKK1-KD) was successfully produced using an E. coli expression system. This
protein was used to screen a library of 378 kinase inhibitors, which identified 86 molecules that bound to CAMKK1 causing a change in protein melting temperature (ΔTm) of greater than 2 °C (see full list in Supplementary Information). Previously, two large scale kinase screening efforts published by Davis et al. 13 and Anastassiadis et al 14 Figure 1B , and the top 20 most potent inhibitors of CAMKK1 are shown in Table 2 .
Among the compounds identified as potent inhibitors of CAMKK1 are the ALK/IGF1R inhibitor AZD3463, the PDGFR inhibitors CP-673451, the PDGFR/FLT3 inhibitor Crenolanib, and the SGK inhibitor GSK650394 15 (which we previously also identified as a CAMKK2 inhibitor). The range of different chemotypes identified as potent CAMKK1
inhibitors suggests CAMKK1 as a common off-target of existing kinase inhibitors, and that development of CAMKK1-specific inhibitors will require a design that incorporates CAMKK1-specific structural features. 
CAMKK1 has a similar overall structure to CAMKK2
Crystallisation trials of CAMKK1-KD with a selection of the strongest binding inhibitors from the DSF analysis yielded crystals in complex with Crenolanib, AZD3463, AP26113, hesperadin and GSK650394. Crystals were also obtained with STO-609 which is well-known as a CAMKK inhibitor 9, 11 . However, crystals that diffracted X-rays to high resolution were only obtained with hesperadin and GSK650394. From these crystals it was possible to determine the crystal structure of CAMKK1 to 2.1 Å resolution in complex with hesperadin and 2.2 Å resolution in complex with GSK650394 ( Table 1 ). The two crystal structures were in different crystal forms, with two or four CAMKK1 molecules in the asymmetric unit. The final model for the co-crystal structure with hesperadin consists of residues 124-163 and 193-411, one molecule of hesperadin per CAMKK1 monomer and 271 water molecules. The disordered residues from 164-192 that are not visible in the structure are the RP-insert domain, which is implicated in substrate recognition. This RP-insert domain was also disordered in the co-crystal structure with GSK650394.
Overall, the CAMKK1 kinase domain has the expected protein kinase fold with an N- Therefore the mechanisms by which CAMKKs interact with calmodulin for activation might be different compared to the mechanism of CAMK1 activation 9 . The calmodulin binding domain in CAMKK1 is at the C-terminus of the protein, comprising the residues 438 VRLIPSWTTVILVKSMLRK 456 , immediately after the auto-inhibitory domain 16 , and was not included in the construct used for crystallisation.
Analysis of inhibitor binding to CAMKK1
In both crystal structures the inhibitors were clearly visible in the electron density and could be convincingly modelled (Figure 3, 4 ). The inhibitors bind as expected in the ATPbinding pocket, between the N-terminal and C-terminal lobes of the kinase domain. In the structure with GSK650394 the inhibitor is bound in a similar manner to that seen in CAMKK2 (PDB ID 6BKU), with two hydrogen bonds to the kinase hinge region, one to the backbone carbonyl atom of Asp231 and the other to the backbone nitrogen atom of Leu233 ( Figure 3C ). There is a favourable aromatic π-π interaction between the benzoic acid ring of GSK650394 and the side-chain of Phe230, and a hydrophobic interaction between the phenyl ring of GSK650394 and Pro237 on the hinge. The carboxylic acid of GSK650394 forms a hydrogen bond with the side-chain of Lys157, for a total of three hydrogen bonds in direct interaction with CAMKK1. There is also a hydrogen bond to a water molecule which is bound by the side-chain of the αC residue Glu199 and the backbone nitrogen of Phe294
( Figure 3D ). ITC measurements showed that CAMKK1 binds GSK650394 strongly, with a KD of 4 nM ( Figure 3F ).
In the structure with hesperadin, the inhibitor again forms two hydrogen bonds to the hinge, via its oxindole moiety to the backbone carbonyl atom of Asp231 and the backbone nitrogen atom of Leu233 ( Figure 4C ). Hesperadin also forms a hydrogen bond via its sulphonamide to the side-chain of Lys157, while the oxindole ring forms a hydrophobic interaction with Phe230 ( Figure 4C, 4D ). ITC measurements showed that CAMKK1 binds hesperadin with a KD of 26 nM ( Figure 4F ).
The most potent CAMKK1 inhibitors bind due to favourable enthalpy
After seeing that hesperadin and GSK650394 were extremely potent inhibitors of CAMKK1, we measured ITC data for four additional inhibitors that bound strongly to CAMKK1 in the DSF assay ( Figure 5 , Table 3 ), to confirm if the low dissociation constants and enthalpy-dependent binding seen with hesperadin and GSK650394 were common features of the identified CAMKK1 inhibitors. The data show that all of the tested inhibitors are extremely potent binders of CAMKK1, and furthermore in all cases the binding is heavily enthalpy-dependent. 
Two active site differences could allow the design of specific inhibitors
The ATP-binding sites of CAMKK1 and CAMKK2 are highly conserved, which is reflected in the similarity of the inhibitor binding profiles of CAMKK1 and CAMKK2 seen previously 13, 14 Comparison of the CAMKK1 structures to CAMKK2 reveals two possible options for the design of specific inhibitors ( Figure 6 ). The first is that there are differences in the hydrophobic "back-pocket" region around the kinase regulatory spine (R-spine). In particular, Leu228 in CAMKK1 is Met265 in CAMKK2 and this difference would presumably affect the movement of the R-spine residues in response to inhibitors that disrupt the R-spine, i.e. type II kinase inhibitors. A type II inhibitor would have the potential to gain selectivity between CAMKK1 and CAMKK2 by taking advantage of this and other nonconserved residues outside the ATP-binding pocket itself.
However, a more significant difference between CAMKK1 and CAMKK2 is seen in the kinase hinge region ( Figure 6B ). The hinge residues Leu233, Arg234 and Lys235 are replaced in CAMKK2 by Val270, Asn271 and Gln272. Although none of these amino acid side-chains are directed into the ATP-binding site, these sequence differences cause a significant difference in the conformation of the protein backbone in this region, greater than 1 Å difference in position. Especially important is CAMKK1 Leu233, which is larger than the equivalent valine residue in CAMKK2 and to be accommodated in the same space requires the different backbone conformation observed. The differences in the hinge residues Arg234 and Lys235 which interact with the β6-β7 loop are also likely to contribute to the different conformation, especially since the key residue on the β6-β7 loop, Asp285, is also not conserved in CAMKK2.
Discussion
The compound screening data showed that a significant number of kinase inhibitors interact with CAMKK1, despite none of these molecules being originally designed as a CAMKK inhibitor. This suggests that CAMKK1 is an easily inhibited kinase, and given the strength of binding observed, that alteration of Ca 2+ /CaM signalling may be a significant cause of some of the phenotypes observed with some of these inhibitors. It also suggests that achieving high potency with a newly designed CAMKK1-specific inhibitor will be possible, especially given the relatively high KM(ATP) previously reported for CAMKK1 6, 17 .
As the ATP-binding sites of CAMKK1 and CAMKK2 are so similar, for future design of a specific inhibitor there are two possibilities: an allosteric inhibitor, or an inhibitor which can take advantage of the small differences that do exist to achieve specificity. The two different crystal structures of CAMKK1 with different inhibitors show a large difference in the position of helix αC ( Figure 6C, 6D ). In the structure with hesperadin αC is in an inactive αC-out conformation, with a disrupted kinase R-spine ( Figure 6D ). The R-spine is a set of four residues in kinases that line up to form a hydrophobic spine when a protein kinase is in an active conformation 18 . Since it appears that hesperadin does not directly push out the αC helix, this indicates flexibility of this region of the protein and therefore that a type II inhibitor (or indeed an allosteric, type III, inhibitor) binding to and disrupting the R-spine would be possible. The inhibitor screening data shows that a number of known type II inhibitors such as ponatinib bind strongly to CAMKK1. Given that there are sequence differences between CAMKK1 and CAMKK2 in this region of the R-spine and αC, this could be a way to achieve selectivity. Finally, the significant differences in the conformation of the C-terminal part of the kinase hinge region (residues Arg234-Gly236, Figure 6B ) could be exploited by suitablydesigned type I kinase inhibitors.
Materials and Methods
DNA constructs
A full length coding DNA clone for human CAMKK1 was obtained from the The data was integrated with XDS 20 and scaled using AIMLESS from the CCP4 software suite 21 . The structure was solved by molecular replacement using Phaser 22 and the kinase domain of CAMKK2 as the search model (PDB ID 2ZV2) 9 . Refinement was performed using REFMAC5 23 and Coot 24 was used for model building. Structure validation was performed using MolProbity 25 .
Protein expression and purification
Isothermal calorimetry
Measurements were made using a MicroCal AutoiITC200 (Malvern, United Kingdom), at 20 ºC with 1000 rpm stirring. For all measurements CAMKK1-KD protein was dialysed overnight against gel filtration buffer, and the dialysis buffer was used to dilute the inhibitors. . Structural differences between CAMKK1 (shown in blue) and CAMKK2 (shown in yellow) that could be exploited to design specific inhibitors. A. Adjacent to the kinase Rspine Leu228 in CAMKK1 is Met265 in CAMKK2. An inhibitor that disrupts the R-spine (a type 2 inhibitor) could engage this amino acid B. Due to different interactions between the hinge region (Arg234 in CAMKK1) and the β4-β5 loop (Asp285 in CAMKK1) the hinge region is significantly further away from the ATP-binding site in CAMKK2 (1.2 Å). This could be exploited by an inhibitor that interacts with the backbone of Arg234 (or Asp285 for a CAMKK2 inhibitor). C. View of the R-spine residues and αC helix of CAMKK1 when bound to GSK650394. D. View from the same angle as C of the R-spine residues and αC helix of CAMKK1 when bound to hesperadin, showing the deformation of the R-spine and the more outward position of αC in the presence of this inhibitor, and the flexibility of these residues.
